04 Nov 2021

UK becomes first to authorize Merck and Ridgeback Biotherapeutics’ antiviral molnupiravir to treat mild-to-moderate Covid-19

The Merck and Ridgeback Biotherapeutics’ oral antiviral, molnupiravir, was authorized by the UK Medicines and Healthcare Products Regulatory Agency on Thursday for treatment of mild and moderate Covid-19 cases. This is the first antiviral oral drug to be authorized for the treatment of Covid-19 and is authorized for adults at

Read More
07 Oct 2020

Eli Lilly Asks FDA to Authorize Covid-19 Antibody Drug

Eli Lilly & Co. has requested that the US FDA release an emergency authorization of an experimental antibody-based treatment for the COVID-19 pandemic. The treatment can be administered to those recently diagnosed with COVID-19 and experiencing mild to moderate symptoms. The drug has been code-named LY-CoV555, and was derived from

Read More